{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T18:05:12Z","timestamp":1790273112307,"version":"4.1.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T00:00:00Z","timestamp":1764633600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.breast.2025.104669","type":"journal-article","created":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T16:10:24Z","timestamp":1765037424000},"page":"104669","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Adjuvant ovarian function suppression and aromatase inhibitors in premenopausal patients with hormone receptor and HER2 positive breast cancer, by timing of chemotherapy and trastuzumab and response to neoadjuvant therapy"],"prefix":"10.1016","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9502-8441","authenticated-orcid":false,"given":"Ayelet","family":"Shai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Wildiers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Venieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Pogoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbro","family":"Linderholm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Lambertini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonor","family":"Matos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"De Maio D'Esposito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nawale","family":"Hajjaji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Matos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc\u00eda","family":"Gonz\u00e1lez Cortijo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Fotia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Fortuna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tal","family":"Sella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Gouveia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Rosset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia","family":"Constantinidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eurydice","family":"Angeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irfan","family":"Cicin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivianne","family":"Tjan-Heijnen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natacha","family":"Ruyssers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofie","family":"Demasure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Areen","family":"Abu Remilah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greet","family":"Huygh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shani","family":"Paluch-Shimon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo","family":"Chiappe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natali","family":"Shirron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Neven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet","family":"Artac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bilgesah","family":"Kilictas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jalal","family":"Baranseh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Vicente-Rubio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"Atci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ottavia","family":"Amato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederieke","family":"van Duijnhoven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.breast.2025.104669_bib1","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1803164","article-title":"Tailoring adjuvant endocrine therapy for premenopausal breast cancer","volume":"379","author":"Francis","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.breast.2025.104669_bib2","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41523-023-00509-2","article-title":"Type of adjuvant endocrine therapy and disease-free survival in patients with early HR-positive\/HER2-positive BC: analysis from the phase III randomized ShortHER trial","volume":"9","author":"Dieci","year":"2023","journal-title":"npj Breast Cancer"},{"issue":"1","key":"10.1016\/j.breast.2025.104669_bib3","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1093\/jnci\/djy094","article-title":"Adjuvant Anti-HER2 therapy, treatment-related amenorrhea, and survival in premenopausal HER2-Positive early breast cancer patients","volume":"111","author":"Lambertini","year":"2019","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"10.1016\/j.breast.2025.104669_bib4","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.2082","article-title":"Adjuvant ovarian function suppression in premenopausal hormone receptor\u2013positive breast cancer","volume":"7","author":"Basmadjian","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"3","key":"10.1016\/j.breast.2025.104669_bib5","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/S1470-2045(21)00758-0","article-title":"Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials","volume":"23","author":"Bradley","year":"2022","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.breast.2025.104669_bib6","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1200\/OP.21.00020","article-title":"Management of early-stage human epidermal growth factor receptor 2\u2013Positive breast cancer","volume":"17","author":"Pernas","year":"2021","journal-title":"JCO Oncol Pract"},{"issue":"2","key":"10.1016\/j.breast.2025.104669_bib7","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.annonc.2023.11.016","article-title":"Early breast cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"35","author":"Loibl","year":"2024","journal-title":"Ann Oncol"},{"issue":"26","key":"10.1016\/j.breast.2025.104669_bib8","doi-asserted-by":"crossref","first-page":"3046","DOI":"10.1200\/JCO.2016.71.9815","volume":"35","author":"Harbeck","year":"2017","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"5","key":"10.1016\/j.breast.2025.104669_bib9","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/S1470-2045(22)00159-0","volume":"23","author":"Nitz","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.breast.2025.104669_bib10","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ejca.2016.03.087","article-title":"HannaH phase III randomised study: association of total pathological complete response with event-free survival in HER2-positive early breast cancer treated with neoadjuvant\u2013adjuvant trastuzumab after 2 years of treatment-free follow-up","volume":"62","author":"Jackisch","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.breast.2025.104669_bib11","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ejca.2017.10.021","volume":"89","author":"Schneeweiss","year":"2018","journal-title":"Eur J Cancer"},{"issue":"7","key":"10.1016\/j.breast.2025.104669_bib12","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa1814017","article-title":"Trastuzumab emtansine for residual invasive HER2-Positive breast cancer","volume":"380","author":"Von","year":"2019","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.breast.2025.104669_bib13","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.annonc.2023.11.016","article-title":"Early breast cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"35","author":"Loibl","year":"2024","journal-title":"Ann Oncol"},{"issue":"13","key":"10.1016\/j.breast.2025.104669_bib14","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.20.03399","article-title":"Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO guideline","volume":"39","author":"Korde","year":"2021","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.breast.2025.104669_bib15","article-title":"Ovarian suppression for adjuvant treatment of hormone receptor-positive early breast cancer","volume":"3","author":"Bui","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"issue":"35","key":"10.1016\/j.breast.2025.104669_bib16","doi-asserted-by":"crossref","first-page":"3948","DOI":"10.1200\/JCO.2014.55.6993","article-title":"Phase III comparison of tamoxifen versus tamoxifen plus ovarian function suppression in premenopausal women with node-negative, hormone receptor\u2013positive breast cancer (E-3193, INT-0142): a trial of the eastern cooperative oncology group","volume":"32","author":"Tevaarwerk","year":"2014","journal-title":"J Clin Oncol"},{"issue":"27","key":"10.1016\/j.breast.2025.104669_bib17","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1200\/JCO.2016.72.0946","article-title":"Treatment efficacy, adherence, and quality of life among women younger than 35 years in the international breast cancer study group TEXT and SOFT adjuvant endocrine therapy trials","volume":"35","author":"Saha","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2025.104669_bib18","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.breast.2022.01.012","article-title":"Factors influencing five-year adherence to adjuvant endocrine therapy in breast cancer patients: a systematic review","volume":"62","author":"Yussof","year":"2022","journal-title":"Breast Edinb Scotl"},{"issue":"2","key":"10.1016\/j.breast.2025.104669_bib19","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s10549-018-05073-z","article-title":"Identifying adherence barriers to oral endocrine therapy among breast cancer survivors","volume":"174","author":"Paranjpe","year":"2019","journal-title":"Breast Cancer Res Treat"},{"issue":"10","key":"10.1016\/j.breast.2025.104669_bib20","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S1470-2045(06)70869-5","article-title":"Survival patterns after oophorectomy in premenopausal women: a population-based cohort study","volume":"7","author":"Rocca","year":"2006","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.breast.2025.104669_bib21","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1097\/AOG.0b013e3182864350","article-title":"Long-term mortality associated with oophorectomy compared with ovarian conservation in the nurses' health study","volume":"121","author":"Parker","year":"2013","journal-title":"Obstet Gynecol"},{"issue":"7","key":"10.1016\/j.breast.2025.104669_bib22","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1001\/jamacardio.2016.2415","article-title":"Association of age at onset of menopause and time since onset of menopause with cardiovascular outcomes, intermediate vascular traits, and all-cause mortality: a systematic review and meta-analysis","volume":"1","author":"Muka","year":"2016","journal-title":"JAMA Cardiol"},{"issue":"11","key":"10.1016\/j.breast.2025.104669_bib23","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1212\/01.wnl.0000276984.19542.e6","article-title":"Increased risk of cognitive impairment or dementia in women who underwent oophorectomy before menopause","volume":"69","author":"Rocca","year":"2007","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.breast.2025.104669_bib24","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S0197-2456(00)00104-5","article-title":"Sample-size calculations for the cox proportional hazards regression model with nonbinary covariates","volume":"21","author":"Hsieh","year":"2000","journal-title":"Control Clin Trials"},{"issue":"10","key":"10.1016\/j.breast.2025.104669_bib25","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1093\/annonc\/mdw262","article-title":"Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial","volume":"27","author":"Dieci","year":"2016","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.breast.2025.104669_bib26","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S1470-2045(17)30021-9","article-title":"HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial","volume":"18","author":"Llombart-Cussac","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.breast.2025.104669_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104205","article-title":"HER2-enriched subtype and novel molecular subgroups drive aromatase inhibitor resistance and an increased risk of relapse in early ER+\/HER2+ breast cancer","volume":"83","author":"Bergamino","year":"2022","journal-title":"EBioMedicine"},{"issue":"1","key":"10.1016\/j.breast.2025.104669_bib28","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1093\/jnci\/djz042","article-title":"HER2-Enriched subtype and ERBB2 expression in HER2-Positive breast cancer treated with dual HER2 blockade","volume":"112","author":"Prat","year":"2020","journal-title":"JNCI J Natl Cancer Inst"},{"issue":"6","key":"10.1016\/j.breast.2025.104669_bib29","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1200\/JCO.2015.62.1268","article-title":"Molecular heterogeneity and response to neoadjuvant human epidermal growth factor receptor 2 targeting in CALGB 40601, a randomized phase III trial of paclitaxel plus trastuzumab with or without lapatinib","volume":"34","author":"Carey","year":"2016","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.breast.2025.104669_bib30","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.annonc.2023.05.012","article-title":"Association of HER2DX with pathological complete response and survival outcomes in HER2-positive breast cancer","volume":"34","author":"Villacampa","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2025.104669_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103801","article-title":"Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer","volume":"75","author":"Prat","year":"2022","journal-title":"EBioMedicine"},{"issue":"1","key":"10.1016\/j.breast.2025.104669_bib32","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.clbc.2020.09.014","article-title":"Final efficacy results of neratinib in HER2-positive hormone receptor-positive early-stage breast cancer from the phase III ExteNET trial","volume":"21","author":"Chan","year":"2021","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.breast.2025.104669_bib34","article-title":"Prognostic value of residual disease (RD) biology and gene expression changes during the neoadjuvant treatment in patients with HER2-positive early breast cancer (EBC)","author":"Fernandez-Martinez","year":"2024","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.breast.2025.104669_bib35","doi-asserted-by":"crossref","first-page":"3590","DOI":"10.3390\/ijms24043590","article-title":"HER2 amplification level predicts pathological complete response in the neoadjuvant setting of HER2-Overexpressing breast cancer: a meta-analysis and systematic review","volume":"24","author":"Gonullu","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"16","key":"10.1016\/j.breast.2025.104669_bib36","doi-asserted-by":"crossref","first-page":"2998","DOI":"10.1200\/JCO.22.02241","article-title":"Pathologic complete response and individual patient prognosis after neoadjuvant chemotherapy plus anti\u2013human epidermal growth factor receptor 2 therapy of human epidermal growth factor receptor 2\u2013Positive early breast cancer","volume":"41","author":"Van Mackelenbergh","year":"2023","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.breast.2025.104669_bib37","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1093\/jnci\/djac096","article-title":"Impact of age on clinical outcomes and efficacy of adjuvant dual Anti-HER2 targeted therapy","volume":"114","author":"Lambertini","year":"2022","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"10.1016\/j.breast.2025.104669_bib38","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1200\/JCO.19.00126","article-title":"Adding ovarian suppression to tamoxifen for premenopausal breast cancer: a randomized phase III trial","volume":"38","author":"Kim","year":"2020","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977625008884?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977625008884?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T16:07:47Z","timestamp":1770998867000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977625008884"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":37,"alternative-id":["S0960977625008884"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2025.104669","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adjuvant ovarian function suppression and aromatase inhibitors in premenopausal patients with hormone receptor and HER2 positive breast cancer, by timing of chemotherapy and trastuzumab and response to neoadjuvant therapy","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2025.104669","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104669"}}